AbbVie Reports Results of Depatux-M (depatuxizumab mafodotin) in P-III INTELLANCE-1 Study for Glioblastoma

 AbbVie Reports Results of Depatux-M (depatuxizumab mafodotin) in P-III INTELLANCE-1 Study for Glioblastoma

AbbVie Reports Results of Depatux-M (depatuxizumab mafodotin) in P-III INTELLANCE-1 Study for Glioblastoma

Shots:

  • The P-III study results involves assessing of Depatux-M (depatuxizumab mafodotin, ABT-414) + SOC therapy of radiation + temozolomide vs PBO + SOC in 639 patients with newly diagnosed EGFR-amplified GBM
  • AbbVie has halted the enrollment of patients in all ongoing studies of Depatux-M due to its inability to meet 1EP, demonstrated no survival benefits & no new safety is observed. IMDC has also recommended for the termination of INTELLANCE-1 study due to lack of survival benefits
  • Depatux-M (depatuxizumab mafodotin) is an ADC targeting EGFR-amplification, evaluated to treat glioblastoma under the collaboration of AbbVie & RTOG foundation

Click here to read full press release/ article | Ref: AbbVie | Image: Punktlandung

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post